Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

To see complete record on, please visit this link

Id: NCT03134066

Organisation Name: Massachusetts General Hospital

Overal Status: Completed

Start Date: September 2016

Last Update: March 11, 2020

Lead Sponsor: Massachusetts General Hospital

Brief Summary: There is an urgent need for novel and effective interventions for treatment-resistant depression (TRD). In previous studies, ketamine has been shown to rapidly reduce depressive symptoms; however, the exact mechanisms of action of ketamine remain unknown. There are some preliminary findings to suggest that ketamine may exert its antidepressant effects through promotion of neurogenesis in the dentate gyrus. The aim of this study is to help delineate the neurocognitive effects of ketamine exposure using a behavioral task (specifically, a pattern separation task) and a battery of other well-established cognitive measures.

This is an assessment-only study, as we will be recruiting subjects to complete an assessment battery at two time points, before and after receiving ongoing ketamine administrations for at least four weeks.

  • Treatment Resistant Depression

Total execution time in seconds: 0.22957992553711